Cargando…

Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease

The non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban have transformed the management of atrial fibrillation (AF), but are only approved by regulatory authorities for stroke prophylaxis in patients with so-called “non-valvular AF.” This terminology...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fanaroff, Alexander C, Vora, Amit N, Lopes, Renato D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850709/ https://www.ncbi.nlm.nih.gov/pubmed/35185406 http://dx.doi.org/10.1093/eurheartj/suab151

Ejemplares similares

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2019)

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation
por: Kim, Hyue Mee, et al.
Publicado: (2019)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
por: Coleman, Craig I., et al.
Publicado: (2019)

Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review
por: Cases, Aleix, et al.
Publicado: (2021)

Correction: Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
Publicado: (2019)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
por: Pan, Kuo‐Li, et al.
Publicado: (2017)

Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration
por: Zhao, Shujuan, et al.
Publicado: (2020)

Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants
por: Darche, Fabrice F., et al.
Publicado: (2023)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation
por: Hidalgo-Vega, Álvaro, et al.
Publicado: (2014)

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
por: Gremmel, Thomas, et al.
Publicado: (2018)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
por: Malagù, Michele, et al.
Publicado: (2023)

Effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with non‐valvular atrial fibrillation: A nationwide, population‐based study in Korea
por: Han, Seongwook, et al.
Publicado: (2021)

Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK
por: Ruigómez, Ana, et al.
Publicado: (2019)

Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care
por: Guimarães, Patrícia O, et al.
Publicado: (2015)

Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea
por: Bae, Hee-Joon, et al.
Publicado: (2018)

Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation
por: Silva Cunha, Pedro, et al.
Publicado: (2022)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism: a meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2021)

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants
por: Faraoni, David, et al.
Publicado: (2015)

Impact of Non-vitamin K Antagonist Oral Anticoagulant Withdrawal on Stroke Outcomes
por: Park, Joong Hyun, et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
por: Botto, Giovanni Luca, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
por: Yang, Hayang, et al.
Publicado: (2019)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists
por: Zulkifly, Hanis H., et al.
Publicado: (2023)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis
por: Santarpia, Giuseppe, et al.
Publicado: (2015)

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
por: Goldstein, Patrick, et al.
Publicado: (2013)

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
por: Patel, Raj
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9d6gruv4tc3ct4qc6o6sm2cdh5